Having trouble accessing articles? Reset your cache.

Deerfield propels Civetta with $53M series A

How Civetta is using its series A from Deerfield to take on β-propeller proteins as a target class

Deerfield-backed Civetta Therapeutics LLC is building a platform to systematically identify small molecules targeting β-propeller proteins, a molecular class that has seen little drug development activity despite its ubiquity in the human genome.

“There has been over time the emergence of data suggesting the propeller domain as a structure might be more amenable to drug discovery than people had previously thought,” said co-founder William Sellers.

Read the full 656 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE